Jortan Pharmaceuticals Inc. — Department of Health and Human Services SBIR Phase I: 200

Description

DESCRIPTION provided by applicant Diabetes is the th leading cause of death in the U S and some million new cases are diagnosed per year Nearly million in the U S have diabetes with annual healthcare costs estimated at $ billion Diabetes patients suffer from complications associated with diminished or dysfunctional insulin levels The prognosis for diabetes patients is grim If not properly managed glucose imbalance will lead to severe complications such as blindness kidney failure amputations heart failure and stroke Current treatment options include diet exercise insulin replacement and glucose modulating drugs There are several classes of glucose lowering drugs on the market that act in different ways to lower blood glucose levels through stimulating production of insulin enhancing insulin activity increasing glucose absorption and or decreasing glucose production in the liver However no current drug therapies address the physiological source of the problem i e deteriorated pancreatic cell mass and function Pancreatic cells produce insulin Development of therapeutics that promote glucose homeostasis through regeneration and or replenishment of insulin producing cells in the pancreas is needed cell regeneration therapy holds promise for replacing the use of pharmaceutical insulin and anti diabetic glucose lowering drugs while simultaneously improving quality of life and reducing complication risk The SBIR goal is to prove the feasibility of using our candidate drugs inhibitors of the enzyme BACE to enhance cell proliferation and mass and to promote glucose homeostasis Preliminary work done by the interdisciplinary Jortan Randamp D team demonstrates the potential for designing selective BACE inhibitors to support this approach For this Phase I feasibility project Jortan will pursue three Aims design inhibitors of BACE and assess potency and selectivity in vitro measure PK and tissue distribution for selected inhibitors and determine feasibility for selected inhibitors to improve glycemic control and enhance cell proliferation This project will provide data to address the key question Can our novel BACE inhibitors effectively reduce blood glucose and serum insulin levels Do these inhibitors enhance pancreatic cell proliferation and or mass Phase I success will lead to a Phase II project focused on a study with increased numbers of mice to validate the results and provide for early safety and toxicity studies These studies along with additional studies funded by engagement with private sector Phase III commercialization partners will be necessary to move the drug through FDA standard IND enabling pharmacokinetic toxicology and mutagenicity studies to lead to clinical trials in human As envisioned development commercialization of a novel BACE inhibitor therapeutic is expected to limit progression of diabetes and ameliorate the associated symptoms decreasing morbidity improving patient quality of life and significantly reducing treatment costs PUBLIC HEALTH RELEVANCE Diabetes affects million people in the U S and hundreds of millions worldwide causing symptoms such as frequent urination extreme fatigue blurry vision and tingling pain and numbness in hands or feet due to an imbalance of insulin and glucose in the blood with more severe complications blindness kidney failure amputations heart failure and stroke developing over time Current therapies do not address the physiological source of the problem deterioration of the insulin producing cells of the pancreas The goal of this Jortan Phase I SBIR project is to demonstrate the feasibility of a novel therapeutic candidate for enhancing cell growth and function promoting insulin production and maintaining normal glucose levels that will provide diabetes patients significantly improved treatment and quality of life while greatly reducing healthcare costs